could favipirivir become a serious contender, page-3

hi jj
i'm not up with the resistance profile of Favipirivir but assume it won't have the stockpiling advantages of lani re - stocked as bulk powder and single application administration. oral is good but what did they have to give up resistance wise to achieve it. i agree with you that gov'ts will want a broad stock of anti virals - soon that only leaves relenza and lani and permirivir and tamiflu stocks will be kept incase new virus is still suseptable to them (but probably not replaced as they expire) - although that will be a long shot as any emerging virus strain is likely to have h274y -due to the new swine flu likely being the major stain for the next decade or so - even if swine and bird flu reassorted -if at that time H274y is firmly fixed in swine there is a good chance combination will also aquire it imo .
how far away is Favipirivir from completing phase 3?

ps i'll be very interested to see how much lag there will be in the new tamiflu news deceminating to the market - i'm guessing at least a week - maybe more - great window to pick up more stock - probably last chance at anything under $3.